Wellcentive

Updated: Philips acquires population health management vendor Wellcentive

The deal will allow Amsterdam-based Philips to augment its offerings in population health management.

Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options

FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.

By FASENRA, Sponsored Content

Tackling Rising Drug Costs and Growing Popularity of GLP-1’s

See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.

By Quantum Health and MedCity News

Consultants: Help Define What’s Next In Healthcare Benefits

Help shape the future of healthcare benefits by sharing your insights.

By MedCity News